Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $11.6 million.

  • Fulcrum Therapeutics' Total Current Liabilities fell 19.83% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 19.83%. This contributed to the annual value of $11.0 million for FY2024, which is 19.24% down from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Total Current Liabilities is $11.6 million, which was up 29.46% from $9.0 million recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Total Current Liabilities high stood at $22.6 million for Q1 2021, and its period low was $8.1 million during Q1 2025.
  • Its 3-year average for Total Current Liabilities is $12.2 million, with a median of $12.7 million in 2024.
  • Per our database at Business Quant, Fulcrum Therapeutics' Total Current Liabilities spiked by 61.44% in 2021 and then plummeted by 33.08% in 2023.
  • Over the past 5 years, Fulcrum Therapeutics' Total Current Liabilities (Quarterly) stood at $19.2 million in 2021, then declined by 12.89% to $16.7 million in 2022, then fell by 18.24% to $13.7 million in 2023, then dropped by 19.24% to $11.0 million in 2024, then dropped by 19.83% to $11.6 million in 2025.
  • Its Total Current Liabilities stands at $11.6 million for Q3 2025, versus $9.0 million for Q2 2025 and $8.1 million for Q1 2025.